87 results
8-K
THER
Theralink Technologies, Inc.
11 Jun 20
OncBioMune Announces Closing of Asset Purchase Agreement with Avant Diagnostics
5:27pm
product candidates or continue our research and development programs.
In addition to the funds raised in our recent private placements, we … . We plan on doing some research and development for other function-based data-generating assays that we may offer as well as for enhancements to our
8-K
EX-99.1
THER
Theralink Technologies, Inc.
1 Jun 11
Other Events
12:00am
. Sermo provides access to its community for clients that need fast, actionable insights.
Further Information
PediatRx, Inc.
Research & Business … Development
Email:info@pediatrx.com
Shareholder Relations
+1 908 975 0753
Email:ir@pediatrx.com
Sermo Contact:
Jon Michaeli
Sermo, Inc.
P: 617-497-1110
E:jmichaeli@sermo.com
8-K
EX-99.1
THER
Theralink Technologies, Inc.
29 Jun 23
Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer
4:01pm
as we take the strategic step to merge with IMAC,” commented Dr. Ruxin. “As we begin a new chapter of shifting our focus from research and development
8-K
EX-99.1
THER
Theralink Technologies, Inc.
2 Nov 10
Other Events
12:00am
are projections of events, revenues, income, future economic, research, development, reformulation, product performance or management's plans … -looking statements to conform these statements to actual results.
Further Information
PediatRx Inc.
Research & Business Development
Email: info
8-K
EX-99.1
THER
Theralink Technologies, Inc.
14 Sep 11
PediatRx enters U.S. co-promotion agreement for AQUORALTM
12:00am
, income, future economics, research, development, reformulation, product performance or management's plans and objectives for future operations. In some …
PediatRx Inc.
Research & Business Development
Email:info@pediatrx.com
Shareholder Relations
+1 908 975 0753
Email:ir@pediatrx.com
8-K
EX-99.1
ojjr0 83e
20 Oct 11
PediatRx reports revenues and second quarter results
12:00am
8-K
EX-99.1
uy4zd2jlz 5jia6djvfh
15 Sep 11
PediatRx appoints Paul J. Richardson to Board of Directors
12:00am
8-K
EX-99.1
3pw8u
19 Jan 12
PediatRx reports revenues and third quarter results
12:00am
8-K
EX-99.1
b55kus9oti40x
26 May 11
PediatRx reports revenues and fiscal year-end results
12:00am
8-K/A
EX-99.1
41tg1xysap
2 Jul 18
Index to Financial Statements
4:05pm
8-K
EX-99.1
jok1uh1rw ou
21 Apr 11
Pediatrx Comments on Fear of Nausea In Cancer Therapy
12:00am
8-K
EX-99.1
8y61bqy
19 Mar 19
Other Events
8:55am
8-K
EX-99.1
ekg lc1f0td381kv1
6 Jul 11
PediatRx obtains state licenses and begins direct sales to wholesalers and distributors through ICS
12:00am
8-K
EX-99.1
fumrb
5 May 11
Other Events
12:00am
8-K
EX-99.1
y68sbla
6 Apr 11
Other Events
12:00am
8-K
EX-99.1
q5r3hnl
6 Jan 11
Pediatrx Inc., Unique Hospital Specialty Pharma, Begins Trading
12:00am
8-K/A
EX-99.2
t3046fu
19 Aug 20
Report of Independent Registered Public Accounting Firm
5:06pm